Dupixent Side Effects Linked To Increased Risk of Transient Blood Eosinophilia: Study
A new study indicates that Dupixent may work as a treatment for severe asthma, despite being linked to some allergic reactions.
Tag Archives: Asthma Drug
-
-
High Doses of Flovent Fail To Help Treat Severe Asthma In Children: Study
A new study warns that high doses of inhalers do not provide additional benefits to children with asthma.
-
FDA Removes Advair, Symbicort Boxed Warnings For Death Risks
The FDA is removing a black box warning from certain asthma inhalers, saying that evidence shows they do not carry the increased risk of severe asthma side effects and death…
-
Singulair Side Effects Linked to Risk of Nightmares, Depression, Aggressive Behavior: Study
A new study warns of neurological side effects linked to the use of Singulair, an asthma drug that may cause depression, nightmares and aggressive behavior.
-
Asthma Inhaler Recall Impacts 600,000 Ventolin HFA 200D Inhalers
GlaxoSmithKline has issued a pharmacy level recall for about 600,000 Ventolin HFA 200D albuterol inhalers after users reported the medication was leaking into the packaging, suggesting that the devices may…
-
Xolair Pediatric Use Approved, Despite Health Risks, Heart Concerns
Xolair has been approved for use in children ages six to 11, despite concerns over side effects which have led some to suggest it be removed from the market.
-
FDA Warns Against Use of Homeopathic Asthma Treatments
The FDA is warning consumers not to use homeopathic drugs to treat asthma, as they may not work and could put their lives in danger.
-
Xolair Side Effects May Cause Heart Problems, Cancer: FDA Warns
The FDA is warning that the asthma drug Xolair may increase the risk of blood vessel problems in the brain and heart.
-
Advair Settlement Agreement Reached With 45 States for $105M
GlaxoSmithKline will pay 45 states $105 million for illegally marketing the asthma drug Advair.
-
Asthmanefrin and EZ Breathe Atomizer Problems Result in FDA Warning
The FDA is warning of severe adverse reactions from Asthmanefrin, which has only been on the market a year.
